Form 10|K for Sangamo Therapeutics INC filed 02/23/2023
SGMO - Sangamo Therapeutics Inc Earnings - FINVIZ.com
SGMO - Sangamo Therapeutics Inc - Stock screener for investors and traders, financial visualizations.
LT2566972T - Kompozicijos, skirtos cinko pirštu modulių susiejimui
Application filed by Sangamo Therapeutics, Inc. 2020-03-10. Publication ... US20200316116A1 2019-04-02 2020-10-08 Sangamo Therapeutics, Inc. Method for ...
We selected a development candidate in 2023 for our wholly-owned, SOD1-silencing gene therapy for ALS, and we expect to file an IND in mid-2025 and then ...
Sangamo to cut jobs again with planned business overhaul
The gene therapy developer will move headquarters and reduce its workforce by 40%, while seeking partners for its Fabry and cell therapy research.
Sangamo Therapeutics, Inc. (SGMO) - Yahoo Finance
Prathyusha Duraibabu CPA, M.B.A., Senior VP, CFO & Principal Accounting Officer, 490.26k, --, 1979. Dr. Nathalie Dubois-Stringfellow Ph.D. Senior ...
Being developed in collaboration with Sangamo Therapeutics, Inc. ... Form 10-K filed with the Securities and Exchange Commission. Under the ...
indications, include among others, Pfizer, Freeline Therapeutics, Intellia Therapeutics, Sangamo Biosciences, Voyager ... Form 10-K for the year ...
Amgen Retirement and Savings Plan
Argos Therapeutics, Inc. Common and preferred stock 16,023 shares ... (Form 11-K) for the year ended December 31, 2016. /s/ ERNST ...
SEC Filings - Sangamo Therapeutics, Inc.
Mar 27, 2003, 10-K. Annual report which provides a comprehensive overview of the company for the past year. Annual Filings.
Nothing about us without us: Advocacy and engagement in genetic ...
... form, apparent and hidden costs of participation, educational ... Bayer, Sangamo shelves sickle cell therapy, joining rivals forced to ...
State of Illinois State Universities Retirement System
#REORG/TELIGENT INC CL A DESP SEC EFF 10/7/02. Equities. 7,610 ... 117,860.00 SANGAMO THERAPEUTICS INC COM. Equities. 42,204. 1,236,577.20 ...
... FiledOriginal,1463378,Roberto Hernandez for Supervisor 2024,Roberto Hernandez for Supervisor 2024,2024-08-01T05:51:46.4894506+00:00,INC642,100.00,01/10/2024 ...
State of Illinois State Universities Retirement System
#REORG/TELIGENT INC CL A DESP SEC EFF 10/7/02. Equities. 7,610 ... 117,860.00 SANGAMO THERAPEUTICS INC COM. Equities. 42,204. 1,236,577.20 ...
Page 1. Table of Contents. SECURITIES AND EXCHANGE COMMISSION. Washington, D. C. 20549. FORM 11-K. ANNUAL REPORT. Pursuant to Section 15 (d) of ...
Sangamo Therapeutics (SGMO) SEC Filings & 10K Form - MarketBeat
Date, Filer, Form Type, View. 11/12/2024 3:53 PM, Sangamo Therapeutics (Subject) VANGUARD GROUP INC (Filed by), Form SC 13G/A. 11/04/2024
Journal 2511 - Intellectual Property Office of Ireland
Sangamo Therapeutics, Inc. 05/09/2013. 3431600 18191181.9. 3431772 ebm ... 3984780 The Goodyear Tire & Rubber Company 12/10/2021. 3984780 ...
WASATCH ADVISORS LP Schedule 13G/A Filing Concerning ...
Total Shares: 18.0m. Subject Company: Sangamo ; Subject Company: Sangamo Therapeutics Inc View ; Filed as of Date: 2023-10-10 ; Event Date: 2023-09-30.
0001628280-21-015869 | 10-Q | iXBRL Viewer
Sangamo Therapeutics INC SEC filing: Form 10-Q on 08/05/2021 (0001628280-21-015869).
0000012927-19-000046 the boeing company voluntary investment ...
... FORM 11-KANNUAL REPORTPursuant to Section 15 (d) of theSecurities Exchange Act of 1934For the fiscal year ended December 31, 2018Commission File No. 1-442 ...
354 questions with answers in FFPE | Science topic - ResearchGate
We commonly used 10% formaldehyde to fix tissue for pathological usage such as IHC or FISH. ... Sangamo Therapeutics · Leonardo Jose Tadeu de ...